Last reviewed · How we verify

MEROPENEM 2 grams TID

BioVersys SAS · Phase 3 active Small molecule

Meropenem is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.

Meropenem is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Bacterial infections (specific indication under investigation by BioVersys SAS in Phase 3).

At a glance

Generic nameMEROPENEM 2 grams TID
Also known asMerrem
SponsorBioVersys SAS
Drug classCarbapenem antibiotic
TargetPenicillin-binding proteins (PBPs)
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhasePhase 3

Mechanism of action

Meropenem is a carbapenem antibiotic that penetrates bacterial cell walls and binds to penicillin-binding proteins, inhibiting cross-linking of peptidoglycan and causing cell wall degradation. This leads to bacterial cell lysis and death. It has activity against a wide range of gram-positive, gram-negative, and anaerobic bacteria.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: